Basel, March 20, 2014-Novartis has announced the launch of the Lucentis ® (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS ...

Diabetic retinopathy is the leading cause of blindness among working age adults and affects nearly 7.7 million people in the U.S. 1,2 The Lucentis 0.3 mg PFS is now the first syringe prefilled ...

The PFS eliminates several steps in the preparation process for the physician. With the Lucentis PFS, physicians attach the injection needle to the syringe and adjust the dose prior to administration.

Like the Lucentis 0.5 mg vial, the 0.5 mg prefilled syringe (PFS) is approved for patients with wet age-related macular degeneration (AMD) and macular edema after retinal vein occlusion (RVO).

One of the many concerns about President Obama’s health care legislation is that it will encourage—if not eventually require—the government to approve the cheapest rather than the best ...

One of two Phase III studies of the drug Lucentis in patiets with diabetic macular edema met its goal, according to Genentech Inc. One of two Phase III studies of the drug Lucentis in patiets with ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the failure, noting positive details and vowing to seek FDA approval ...

Novartis announces the launch in Europe of the Lucentis pre-filled syringe (PFS), which is specifically designed for intraocular injection The Lucentis PFS can lead to improved patient treatment ...

Basel, March 20, 2014-Novartis has announced the launch of the Lucentis ® (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS, which ...

Novartis announces the launch in Europe of the Lucentis pre-filled syringe (PFS), which is specifically designed for intraocular injection - The Lucentis PFS can lead to improved patient treatment ...

Novartis International AG / Novartis introduces Lucentis® in state of the art pre-filled syringe . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible ...